CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »

Latest:

Dual anti-CGRP therapy proving effective in migraine control CONFIDENCE analysis supports rimegepant consistency, satisfaction and tolerability Impact of anti-CGRP therapies on weather- and fasting-related headaches FINESSE study shows fremanezumab effectiveness in ‘switch’ patients What works best for patients with MOH?Triptan cycling may increase migraine care needs and costs IHS urges ambitious goals for migraine prevention CGRP mAb response rate increases over three years

fMRIred

Caption 2. Increases in CBF (red) and decreases in CBF (blue) during the premonitory phase relative to baseline in the post-hoc paired t-test (n=25).

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie.

Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.

Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

fMRIred

Trials

Meeting Reports

Resources